Paik PK, Yang M, Knowles E, et al. - Data on patient-reported outcomes (PROs) and utilities in patients with NSCLC harboring METex14 skipping mutation treated with tepotinib were provided for the first time ever in this trial (VISION) of a MET inhibitor.

• From the VISION trial, a phase II trial that demonstrated durable clinical activity of tepotinib in advanced NSCLC METex14+, PROs were obtained.

• Using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaires, patients were examined.

• Experts derived the Quality of Life Utility Measure-Core 10 dimensions and EQ-5D-5L utilities by utilizing the utility algorithm from published literature and the US crosswalk, respectively.

• They estimated utilities for 150 of 152 pts, with 983 observations for EORTC and 907 for EQ-5D.

• EORTC and EQ-5D (minimally essential difference: 0.08) utilities demonstrated an increase in health-related quality of life from baseline during tepotinib use until progression.

• Both questionnaires were generally highly correlated.

• No variation in utility with tepotinib was found based on prior treatment status or histology.